Long-Term Observational Study of Tobramycin Inhalation for Clearing Pseudomonas Aeruginosa in Adults With Bronchiectasis

What this Trial Is About

This research aims to study the long-term effects of successfully removing Pseudomonas aeruginosa PA infections in adults with bronchiectasis. It builds on a previous trial called ERASE that tested inhaled Tobramycin to clear PA in patients newly diagnosed with this infection. The goal is to see if eradicating PA improves health outcomes over a longer period. The study involves an extended observation period totaling 36 months, combining the first 9 months from the initial ERASE trial with an additional 27 months of follow-up. Participants are grouped based on whether they successfully cleared PA in the prior study. There is no new treatment given during this follow-up phase it is an observational study tracking patients over time. Participants will be monitored regularly for quality of life, lung function, frequency and severity of lung flare-ups, hospital visits, and treatment costs. Researchers will also check sputum samples at various time points up to 36 months to detect any return of PA infection. This comprehensive follow-up will help understand the long-term benefits and challenges after PA eradication in bronchiectasis patients.

Long-term Impact of Inhaled Tobramycin for Pseudomonas Aeruginosa Eradication in Bronchiectasis (ERASE II)